Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
Jean‐François Rahier(CHU Dinant Godinne UCL Namur), Fernando Magro(Hospital de São João), Cândida Abreu(Hospital de São João), Alessandro Armuzzi, Shomron Ben‐Horin(Sheba Medical Center), Yehuda Chowers(Rambam Health Care Campus), Mario Cottone(University of Palermo), Lissy de Ridder(Erasmus MC - Sophia Children’s Hospital), Glen Doherty(University College Dublin), Robert Ehehalt(University Hospital Heidelberg), María Esteve(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Κωνσταντίνος Κατσάνος(University Hospital of Ioannina), Charlie W. Lees(Western General Hospital), Eithne MacMahon(Guy's and St Thomas' NHS Foundation Trust), Tom G. Moreels(Antwerp University Hospital), Walter Reinisch(McMaster University), Herbert Tilg(Innsbruck Medical University), Lydjie Tremblay(Centre Hospitalier de l’Université de Montréal), G. Veereman-Wauters, N. Viget(Centre Hospitalier de Tourcoing), Yazdan Yazdanpanah(Université Claude Bernard Lyon 1), Rami Eliakim(Sheba Medical Center), Jean‐Frédéric Colombel(Icahn School of Medicine at Mount Sinai)
Cited by 919Open Access
Abstract
From genome wide association studies there is increasing evidence of an aberrant immune response in IBD. 4 Susceptibility loci involve both the innate and adaptive immune response towards a diminished diversity of commensal microbiota. 5 Description of the numerous mechanisms contributing to this dysimmunity is beyond the scope of this article. Despite evidence of defective mucosal immunity, there is no proof of a systemic immune defect in patients with IBD in the absence of concomitant immunomodulator therapy.
Related Papers
No related papers found
Powered by citation graph analysis